Immunomedics Reports Final Survival Data With Yttrium-90-Labeled Clivatuzumab Tetraxetan and Low-Dose Gemcitabine in Advanced Pancreatic Cancer

Immunomedics, Inc. IMMU today announced that treatment with its proprietary humanized antibody, clivatuzumab tetraxetan, labeled with yttrium-90 and combined with low-dose gemcitabine, demonstrated promising therapeutic activity in patients with advanced, inoperable, pancreatic cancer. Despite recent advances in combination chemotherapy of advanced pancreatic cancer, minimal survival improvement has been achieved. In our first clinical trial, 90Y-clivatuzumab tetraxetan was evaluated as a single agent and administered in a single infusion to patients with unresectable locally advanced or metastatic disease.